MedPath

Pediatric Subjects With Tinea Corporis

Phase 4
Completed
Conditions
Tinea Corporis
Interventions
Drug: Placebo Cream
Registration Number
NCT02227290
Lead Sponsor
Merz North America, Inc.
Brief Summary

The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured.

Detailed Description

The objectives of this study are to evaluate the safety and efficacy of Naftin (naftifine hydrochloride) Cream, 2% applied once daily for 2 weeks, compared to its vehicle in the treatment of pediatric subjects aged 2 to 17 years and 11 months with positive potassium hydroxide (KOH), positive dermatophyte culture, and clinical signs and symptoms of tinea corporis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Males or non-pregnant females 2 years of age to 17 years, 11 months, of any race. Females of child bearing potential must have a negative urine pregnancy test.
  • Presence of tinea corporis by clinical evidence of a tinea infection of at least moderate erythema, moderate induration, and mild pruritus.
  • KOH positive and culture positive baseline skin scrapings obtained form the site with the mose severely affected lesion or a representative site of the overall severity.
Exclusion Criteria
  • Tinea infection of the face, scalp, groin, and/or feet
  • A life-threatening condition in the opinion of the investigator (ex. autoimmune deficiency syndrome, cancer, etc) within the last 6 months.
  • Subjects with abnormal findings- physical or laboratory- that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results
  • Subjects with a known hypersensitivity or other contradictions to study medications or their components.
  • Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
  • Uncontrolled diabetes mellitus.
  • Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
  • Current diagnosis of immunocompromising conditions.
  • Current evidence of compromised skin, atopic or contact dermatitis, eczema, impetigo, lichen planus, pityriasis rosea, pityriasis versicolor, psoriasis, seborrhoeic dermatitis and syphilis.
  • Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection
  • Patients with tinea corporis who have concurrent dermatophytosis of the scalp, beard or nails.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Naftin Cream, 2%Naftin CreamOnce Daily
Placebo CreamPlacebo CreamOnce Daily
Primary Outcome Measures
NameTimeMethod
Primary EfficacyDay 21

Complete cure defined by negative KOH result and negative dermatophyte culture

Secondary Outcome Measures
NameTimeMethod
Secondary EfficacyDay 21

Treatment Effectiveness defined as negative KOH, negative culture, and improved sign and symptoms.

Trial Locations

Locations (19)

Merz Investigative Site#507001

πŸ‡΅πŸ‡¦

Panama City, Panama

Merz Investigative Site#001279

πŸ‡΅πŸ‡·

Cidra, Puerto Rico

Merz Investigative Site#001097

πŸ‡ΊπŸ‡Έ

Nashville, Tennessee, United States

Merz Investigative Site#001316

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Merz Investigative Site#001312

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Merz Investigative Site#180002

πŸ‡©πŸ‡΄

San Cristobal, Dominican Republic

Merz Investigative Site# 180001

πŸ‡©πŸ‡΄

Santo Domingo, Dominican Republic

Merz Investigative Site#001314

πŸ‡ΊπŸ‡Έ

Henderson, Nevada, United States

Merz Investigative Site#001311

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Merz Investigative Site #001310

πŸ‡ΊπŸ‡Έ

Miramar, Florida, United States

Merz Investigative Site#001313

πŸ‡ΊπŸ‡Έ

Fremont, California, United States

Investigative Site# 0010320

πŸ‡ΊπŸ‡Έ

Encino, California, United States

Merz Investigative Site#001301

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

Merz Investigative Site#001309

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

Merz Investigative Site#001307

πŸ‡ΊπŸ‡Έ

Saint Joseph, Missouri, United States

Merz Investigative Site#001126

πŸ‡ΊπŸ‡Έ

Raleigh, North Carolina, United States

Investigative Site# 0010319

πŸ‡ΊπŸ‡Έ

Gresham, Oregon, United States

Merz Investigative Site#001293

πŸ‡ΊπŸ‡Έ

Winston Salem, North Carolina, United States

Merz Investigative Site#504001

πŸ‡­πŸ‡³

San Pedro Sula, Honduras

Β© Copyright 2025. All Rights Reserved by MedPath